阅读说明：本技术 具有多浓度检测线的拉莫三嗪侧向层析试纸条及其应用 (Lamotrigine lateral chromatography test strip with multiple concentration detection lines and application thereof ) 是由 陈伟 夏泉 陈琦 任刘丽 姚丽 张超 徐建国 吴玉晗 于 2021-08-17 设计创作，主要内容包括：本发明公开了一种具有多浓度检测线的拉莫三嗪侧向层析试纸条及其应用。所述试纸条包括沿设定方向依次连接的样品垫、金标垫、层析垫和吸水垫,所述层析垫上沿所述设定方向依次间隔分布有低浓度检测线、高浓度检测线和质控线。利用本发明的试纸条可以进行血液等样品中拉莫三嗪浓度的快速判断,整个检测过程仅需10分钟左右,进而可以快速、准确地为患者调整拉莫三嗪的服药剂量提供直接判断依据,对于临床拉莫三嗪服药剂量的控制具有重要的指导和参考价值。(The invention discloses a lamotrigine lateral chromatography test strip with multiple concentration detection lines and application thereof. The test strip comprises a sample pad, a gold label pad, a chromatography pad and a water absorption pad which are sequentially connected along a set direction, wherein low-concentration detection lines, high-concentration detection lines and quality control lines are sequentially distributed on the chromatography pad along the set direction at intervals. The test strip can be used for quickly judging the concentration of lamotrigine in samples such as blood and the like, the whole detection process only needs about 10 minutes, and further, a direct judgment basis can be quickly and accurately provided for a patient to adjust the administration dosage of lamotrigine, and the test strip has important guidance and reference values for controlling the clinical administration dosage of lamotrigine.)

1. The utility model provides a lamotrigine side direction chromatography test paper strip with many concentration detection lines, includes along sample pad, gold mark pad, chromatography pad and the pad that absorbs water that set for the direction and connect gradually, its characterized in that: and the chromatography pad is sequentially provided with low-concentration detection lines, high-concentration detection lines and quality control lines at intervals along the set direction.

2. The lamotrigine lateral flow assay test strip with multiple concentration detection lines of claim 1, wherein:

the detection threshold corresponding to the low-concentration detection line is that the concentration of lamotrigine is below 2.5 mug/mL, and the detection threshold corresponding to the high-concentration detection line is that the concentration of lamotrigine is above 15 mug/mL;

and/or the fixed concentration of the lamotrigine-bovine serum albumin conjugate on the low-concentration detection line is 0.1-0.5mg/mL, and the fixed concentration of the lamotrigine-bovine serum albumin conjugate on the high-concentration detection line is 0.8-1.2 mg/mL.

3. The lamotrigine lateral flow assay test strip with multiple concentration detection lines of claim 1, wherein: the fixed concentration of the rabbit anti-bovine serum albumin antibody on the quality control line is 0.5-1.2 mg/mL.

4. The lamotrigine lateral flow assay test strip with multiple concentration detection lines of claim 1, wherein: the gold label pad is distributed with a colloidal gold label formed by compounding a lamotrigine monoclonal antibody, a rabbit anti-bovine serum albumin antibody and a nano-gold particle, wherein the colloidal gold label comprises 60-70 v/v% of a first colloidal gold label and 30-40 v/v% of a second colloidal gold label, the particle size of the nano-gold particle contained in the first colloidal gold label is 1-10nm, and the particle size of the nano-gold particle contained in the second colloidal gold label is 20-50 nm.

5. The lamotrigine lateral flow assay test strip with multiple concentration detection lines of claim 1, wherein: the two ends of the chromatography pad are respectively lapped with the gold label pad and the water absorption pad; and/or, the chromatographic pad adopts a nitrocellulose membrane; and/or the sample pad, the gold label pad, the chromatography pad and the absorbent pad are all arranged on the bottom plate.

6. The lamotrigine lateral flow assay test strip with multiple concentration detection lines of claim 1, wherein: the distances between the low-concentration detection line, the high-concentration detection line, the quality control line and the gold mark pad are respectively 0.8-1.3mm, 5.2-6.2mm and 16.5-17.5 mm.

7. A kit for detecting the concentration of lamotrigine in blood, characterized by comprising the lamotrigine lateral flow chromatography test strip with multiple concentration detection lines of any one of claims 1-6.

8. The method for preparing the lamotrigine lateral flow assay strip with multiple concentration detection lines of any one of claims 1-6, comprising:

uniformly applying colloidal gold marker dispersion liquid onto a gold label pad and drying, wherein the colloidal gold marker dispersion liquid comprises a colloidal gold marker formed by compounding a lamotrigine monoclonal antibody, a rabbit anti-bovine serum albumin antibody and nano-gold particles;

respectively applying lamotrigine-bovine serum albumin conjugate solution and rabbit anti-bovine serum albumin antibody solution on a chromatographic pad to form a low-concentration detection line, a high-concentration detection line and a quality control line;

and connecting the sample pad, the gold label pad, the chromatography pad and the water absorption pad in sequence to prepare the lamotrigine lateral chromatography test strip.

9. A product is applied to a detection method of lamotrigine concentration in a liquid sample, and is characterized in that: the product comprises the lamotrigine lateral chromatography test strip with multiple concentration detection lines of any one of claims 1-6; the detection method comprises the following steps:

directly dripping a liquid sample to be detected on a sample pad, and observing the color development conditions of a low-concentration detection line, a high-concentration detection line and a quality control line on a chromatography pad after waiting for enough time so as to judge the concentration of lamotrigine in the liquid sample;

wherein when the concentration of lamotrigine in the liquid sample is less than the detection threshold of the low concentration detection line, the high concentration detection line and the quality control line are all visualized;

when the concentration of lamotrigine in the liquid sample is greater than or equal to the detection threshold of the low concentration detection line but less than the detection threshold of the high concentration detection line, the low concentration detection line is not developed, and both the high concentration detection line and the quality control line are developed;

when the concentration of lamotrigine in the liquid sample is greater than or equal to the detection threshold of the high concentration detection line, neither the low concentration detection line nor the high concentration detection line is visualized, and the quality control line is visualized.

10. The product of claim 9, wherein: the liquid sample comprises blood or serum; and/or, the sufficient time is 5-15 min.

Technical Field

The invention relates to a test strip, in particular to a lamotrigine lateral chromatography test strip with a multi-concentration detection line and application thereof, and belongs to the technical field of drug detection.

Background

Therapeutic Drug Monitoring (TDM) is an emerging clinical pharmacy branch subject, and in clinical treatment, TDM quantitatively analyzes the concentration of a drug and a related active metabolite in a biological sample by a high-sensitivity modern analysis technology, and determines the effective treatment concentration range of the used drug by combining clinical indexes so as to ensure that the drug dose is proper, avoid drug toxic and side effects and improve the drug curative effect.

At present, the main medicine for monitoring the medicine in clinical treatment is the medicine with low therapeutic index, narrow safe concentration range and strong adverse reaction. The dosage of the medicine is adjusted in time according to the monitored blood concentration, so that the aim of achieving the optimal treatment effect by using the ideal blood concentration is fulfilled.

Lamotrigine (Lamotrigine) is a novel phentriazine broad-spectrum antiepileptic drug and is mainly used for single-drug treatment or adjuvant treatment of partial and systemic epileptic seizures in clinic. Compared with other known antiepileptics, lamotrigine has the advantages of good tolerance, small influence by metabolic enzymes, small toxicity in pregnancy and the like. It is noteworthy that patients of low age, gestational age, concomitant use of valproate or oxcarbazepine, overdose initially, or with a rapid dose escalation are prone to adverse skin reactions. And due to individual differences, physiological and pathological states and gene polymorphism of different patients, even if lamotrigine is administered according to a recommended dosing scheme strictly, obvious individual differences still exist between the pharmacokinetic behavior and the optimal therapeutic concentration, the difference of blood concentration of the same dose for different patients is likely to be larger, and different therapeutic effects or adverse reactions are likely to be shown.

Therefore, particular attention should be paid to the detection of blood levels of lamotrigine in patients with particular physiological and pathological conditions and altered co-medication. At present, the clinical detection methods of lamotrigine blood concentration mainly comprise an HPLC method, an HPLC-MS/MS method and the like, and the methods are characterized in that the required blood sample amount is large, the sample pretreatment is complex, expensive equipment is required to be equipped, and the methods cannot be realized in all medical institutions.

Disclosure of Invention

The invention mainly aims to provide a lamotrigine lateral chromatography test strip with multiple concentration detection lines and application thereof, so as to overcome the defects in the prior art.

In order to achieve the purpose, the technical scheme adopted by the invention comprises the following steps:

the invention provides a lamotrigine lateral chromatography test strip with multiple concentration detection lines, which comprises a sample pad, a gold label pad, a chromatography pad and a water absorption pad which are sequentially connected along a set direction, wherein the chromatography pad is sequentially provided with low concentration detection lines, high concentration detection lines and quality control lines at intervals along the set direction.

Furthermore, the detection threshold corresponding to the low concentration detection line is that the concentration of lamotrigine is below 2.5 mug/mL, and the detection threshold corresponding to the high concentration detection line is that the concentration of lamotrigine is above 15 mug/mL.

Furthermore, colloidal gold markers formed by compounding lamotrigine monoclonal antibodies, rabbit anti-bovine serum albumin antibodies (BSA) and nano-gold particles are distributed on the gold label pad, wherein the particle size of the nano-gold particles is 1-50 nm.

The invention also provides a kit for detecting the concentration of lamotrigine in blood, which comprises the lamotrigine lateral chromatography test strip with multiple concentration detection lines.

In another aspect of the present invention, a method for preparing the lamotrigine lateral chromatography test strip with multiple concentration detection lines is provided, which comprises:

uniformly applying colloidal gold marker dispersion liquid onto a gold label pad and drying, wherein the colloidal gold marker dispersion liquid comprises a colloidal gold marker formed by compounding a lamotrigine monoclonal antibody, a rabbit anti-bovine serum albumin antibody and nano-gold particles;

respectively applying lamotrigine-bovine serum albumin conjugate solution and rabbit anti-bovine serum albumin antibody solution on a chromatographic pad to form a low-concentration detection line, a high-concentration detection line and a quality control line;

and connecting the sample pad, the gold label pad, the chromatography pad and the water absorption pad in sequence to prepare the lamotrigine lateral chromatography test strip.

In yet another aspect, the invention provides a product for use in a method for detecting the concentration of lamotrigine in a liquid sample, the product comprising the lamotrigine lateral chromatography test strip with multiple concentration detection lines; the detection method comprises the following steps:

directly dripping a liquid sample to be detected on a sample pad, and observing the color development conditions of a low-concentration detection line, a high-concentration detection line and a quality control line on a chromatography pad after waiting for enough time so as to judge the concentration of lamotrigine in the liquid sample;

wherein when the concentration of lamotrigine in the liquid sample is less than the detection threshold of the low concentration detection line, the high concentration detection line and the quality control line are all visualized;

when the concentration of lamotrigine in the liquid sample is greater than or equal to the detection threshold of the low concentration detection line but less than the detection threshold of the high concentration detection line, the low concentration detection line is not developed, and both the high concentration detection line and the quality control line are developed;

when the concentration of lamotrigine in the liquid sample is greater than or equal to the detection threshold of the high concentration detection line, neither the low concentration detection line nor the high concentration detection line is visualized, and the quality control line is visualized.

Compared with the prior art, the lamotrigine lateral chromatography test strip provided by the invention has a plurality of detection lines for indicating different lamotrigine concentrations, can be used for quickly and visually judging the concentration of lamotrigine in samples such as blood and the like, does not need to carry out complex pretreatment on the samples, and has very high clinical application value and market value.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments described in the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.

Fig. 1 is a schematic structural diagram of a lamotrigine lateral chromatography test strip with multiple concentration detection lines according to an embodiment of the present invention;

FIG. 2 is a diagram illustrating the relationship between the results of different concentration detection lines and the judgment of concentration ranges according to an exemplary embodiment of the present invention;

fig. 3 is a graph showing the results of lamotrigine detection in blood using lamotrigine lateral flow assay strips with multiple concentration detection lines according to an embodiment of the present invention.

Detailed Description

As described above, in view of the shortcomings of the prior art, the present inventors have long studied and extensively practiced to provide the technical solutions of the present invention, and as follows, the technical solutions, the implementation processes and principles thereof will be further explained.

The embodiment of the invention provides a lamotrigine lateral chromatography test strip with multiple concentration detection lines, which comprises a sample pad, a gold label pad, a chromatography pad and a water absorption pad which are sequentially connected along a set direction, wherein the chromatography pad is sequentially provided with low concentration detection lines, high concentration detection lines and quality control lines at intervals along the set direction.

Furthermore, two ends of the chromatography pad are respectively lapped with the gold label pad and the water absorption pad.

Furthermore, the sample pad, the gold label pad, the chromatography pad and the absorbent pad are all arranged on the bottom plate.

Wherein, one end of the sample pad can be lapped on the gold label pad, one end of the gold label pad can be lapped on one end of the chromatography pad, and one end of the absorbent pad is lapped on the other end of the chromatography pad. As is well known to those skilled in the art, when a liquid sample is applied to a sample pad, the absorbent pad can cause water, compounds, proteins, etc. in the liquid sample to migrate toward the chromatographic pad by capillary action.

Further, the chromatographic pad adopts a nitrocellulose membrane.

Further, the gold-labeled pad may also be made of nitrocellulose membrane, and the sample pad, the absorbent pad, and the bottom plate may be made of materials commonly used in the art, which are not described herein again.

Further, the detection threshold corresponding to the low concentration detection line is that the concentration of lamotrigine is preferably below 2.5 μ g/mL, and the detection threshold corresponding to the high concentration detection line is that the concentration of lamotrigine is preferably above 15 μ g/mL.

Further, the fixed concentration of the lamotrigine-bovine serum albumin conjugate on the low concentration detection line is preferably 0.1-0.5mg/mL, and the fixed concentration of the lamotrigine-bovine serum albumin conjugate on the high concentration detection line is preferably 0.8-1.2 mg/mL.

Further, the fixed concentration of the rabbit anti-bovine serum albumin antibody on the quality control line is preferably 0.5-1.2 mg/mL.

Furthermore, colloidal gold markers formed by compounding lamotrigine monoclonal antibodies, rabbit anti-bovine serum albumin antibodies and nano-gold particles are distributed on the gold label pad.

Preferably, the distances between the low-concentration detection line, the high-concentration detection line, the quality control line and the gold mark pad are respectively 0.8-1.3mm, 5.2-6.2mm and 16.5-17.5mm, so that the output speed and the accuracy of the detection result can be improved simultaneously.

Preferably, the colloidal gold label comprises 60-70 v/v% of a first colloidal gold label and 30-40 v/v% of a second colloidal gold label, wherein the particle size of the gold nanoparticles contained in the first colloidal gold label is 1-10nm, and the particle size of the gold nanoparticles contained in the second colloidal gold label is 20-50 nm. By adopting the scheme, the problems of false negative, false positive and the like in the detection of the test strip can be effectively reduced or even eliminated.

The embodiment of the invention also provides a kit for detecting the concentration of lamotrigine in blood, which comprises the lamotrigine lateral chromatography test strip with multiple concentration detection lines.

In addition, other components such as a fingertip hemospast, syringe, dropper, cotton swab, etc., or water, buffers, etc., for diluting or dissolving certain pasty, or solid substances may also be included in the kit.

The embodiment of the invention also provides a method for preparing the lamotrigine lateral chromatography test strip with the multi-concentration detection line, which comprises the following steps:

uniformly applying colloidal gold marker dispersion liquid onto a gold label pad and drying, wherein the colloidal gold marker dispersion liquid comprises a colloidal gold marker formed by compounding a lamotrigine monoclonal antibody, a rabbit anti-bovine serum albumin antibody and nano-gold particles;

respectively applying lamotrigine-bovine serum albumin conjugate solution and rabbit anti-bovine serum albumin antibody solution on a chromatographic pad to form a low-concentration detection line, a high-concentration detection line and a quality control line;

and connecting the sample pad, the gold label pad, the chromatography pad and the water absorption pad in sequence to prepare the lamotrigine lateral chromatography test strip.

Further, the colloidal gold marker dispersion may be prepared by a method comprising:

preparing a colloidal gold solution containing the nano gold particles with the required particle size according to the invention in a manner well known in the art;

and mixing the colloidal gold solution with a lamotrigine monoclonal antibody and a rabbit anti-bovine serum albumin antibody for reaction until red precipitates are generated, and then dispersing the red precipitates in a BSA (bovine serum albumin) solution to obtain a colloidal gold marker dispersion liquid.

More specifically, after the colloidal gold solution is prepared, an alkaline solution (for example, a potassium carbonate solution) is added to the colloidal gold solution, then a lamotrigine monoclonal antibody solution is added to the colloidal gold solution to carry out a mixing reaction, then a BSA solution is added to the colloidal gold solution to continue the reaction, and then a red precipitate is separated by high-speed centrifugation and is dispersed in the BSA solution to obtain a colloidal gold-labeled substance dispersion.

Further, the high concentration detection line, the low concentration detection line and the quality control line can be prepared by the following method, including: the preparation method comprises the steps of taking lamotrigine-bovine serum albumin conjugate solution to be respectively diluted to 0.8-1.2mg/mL and 0.1-0.5mg/mL, taking anti-BSA antibody to be diluted to the concentration of 0.8-1.6mg/mL, spraying the anti-BSA antibody solution to a nitrocellulose membrane by using a colloidal gold spraying membrane instrument respectively to be used as a high-concentration detection line, a low-concentration detection line and a quality control line respectively, and then drying the nitrocellulose membrane at a proper temperature, for example, drying the nitrocellulose membrane at 27 ℃ for 2 hours for later use.

The embodiment of the invention also provides a product, which is applied to a detection method of lamotrigine concentration in a liquid sample, and the product comprises the lamotrigine lateral chromatography test strip with the multi-concentration detection line; the detection method comprises the following steps:

directly dripping a liquid sample to be detected on a sample pad, and observing the color development conditions of a low-concentration detection line, a high-concentration detection line and a quality control line on a chromatography pad after waiting for enough time so as to judge the concentration of lamotrigine in the liquid sample;

wherein when the concentration of lamotrigine in the liquid sample is less than the detection threshold of the low concentration detection line, the high concentration detection line and the quality control line are all visualized;

when the concentration of lamotrigine in the liquid sample is greater than or equal to the detection threshold of the low concentration detection line but less than or equal to the detection threshold of the high concentration detection line, the low concentration detection line is not developed, and both the high concentration detection line and the quality control line are developed;

when the concentration of lamotrigine in the liquid sample is greater than the detection threshold of the high concentration detection line, neither the low concentration detection line nor the high concentration detection line is displayed, and the quality control line is displayed.

Further, the liquid sample includes, but is not limited to, blood or serum.

Further, the sufficient time is preferably 5-15min, although it may be longer or shorter depending on the liquid sample.

Further, the detection method can be used for direct detection of blood samples collected from an animal, such as patient fingertip blood, without complicated pre-processing.

The invention provides a colloidal gold lateral chromatography test strip with a plurality of detection lines representing different concentrations, which can be used for quickly judging the concentration of lamotrigine in samples such as blood and the like. Specifically, a plurality of detection lines are arranged on a chromatography pad (also called a detection pad) of the test strip, the detection concentrations represented by different detection lines are different, the concentration of lamotrigine in blood can be rapidly judged according to the display results representing different concentration detection lines, the whole detection process only needs about 10 minutes, and then a direct judgment basis can be rapidly and accurately provided for a patient to adjust the dosage of lamotrigine, and the test strip has important guidance and reference values for controlling the dosage of lamotrigine in clinic.

The technical solutions of the present invention will be described in further detail below with reference to several preferred embodiments and accompanying drawings, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. It is to be noted that the following examples are intended to facilitate the understanding of the present invention, and do not set forth any limitation thereto. All other embodiments, which can be obtained by a person skilled in the art without any inventive step based on the embodiments of the present invention, are within the scope of the present invention. The experimental methods of the following examples, which do not indicate specific conditions, are generally performed according to conventional conditions or according to the conditions recommended by manufacturers, and the experimental conditions and the setting parameters should not be construed as limiting the basic technical solution of the present invention.

Example 1 referring to fig. 1, the lamotrigine lateral flow assay strip with multiple concentration detection lines provided in this example includes a PVC base plate, a sample pad, a gold-labeled pad, a chromatography pad, and a water absorption pad. Wherein, sample pad, gold mark pad, chromatography pad and absorbent pad connect gradually, and the both ends of gold mark pad overlap joint with sample pad, chromatography pad respectively, and chromatography pad and absorbent pad overlap joint. The chromatography pad is sequentially distributed with low-concentration detection lines, high-concentration detection lines and quality control lines at intervals.

The test strip can be prepared by the following method, and comprises the following steps:

(1) preparation of gold nanoparticles for labeling: 70mL of double distilled water is poured into a 250mL conical flask, 1200 mu L of chloroauric acid with the concentration of 10mg/mL is dripped into the double distilled water, and the double distilled water is placed on a magnetic heating stirrer to be heated to slight boiling. After the liquid in the conical flask is slightly boiled, keeping the stirring speed of 1500r/min unchanged, and then quickly adding 1000 mu L of trisodium citrate solution with the mass concentration of 20 g/L. The color of the solution is changed obviously within 2min from transparent-black-purple-wine red to unchanged color, the heat source is closed, the solution is stirred for 15min, and the solution is cooled to obtain the colloidal gold solution, wherein the particle size distribution of the contained nano gold particles is 18-40nm, and the colloidal gold solution is stored at 4 ℃ for standby.

(2) Preparation of colloidal gold marker: putting 1000 mu L of the colloidal gold solution prepared in the step (1) into a clean and dry 1.5mL centrifuge tube, adding 3 mu L of potassium carbonate solution with the concentration of 0.1M, uniformly mixing by oscillation, adding 1.5-5 mu L of lamotrigine monoclonal antibody solution with the concentration of about 1mg/mL, reacting for 2 hours by oscillation, adding 100 mu L of BSA solution with the concentration of 10 wt%, continuing to react by oscillation for 1 hour, centrifuging for 10 minutes at 10100r/min, separating out red precipitate, and redissolving by 100 mu L of BSA solution with the concentration of 10 wt%, thus obtaining colloidal gold marker dispersion;

(3) preparing a gold label pad: and dropwise adding the colloidal gold marker dispersion liquid to a nitrocellulose membrane for preparing the gold-labeled pad according to the dosage of 8 mu L/pad, and drying in an oven at 27 ℃ to obtain the gold-labeled pad for later use.

(4) Preparation of the chromatographic pad: and (2) taking lamotrigine-bovine serum albumin conjugate solution to respectively dilute to 1.2mg/mL and 0.5mg/mL, respectively spraying the solution onto a nitrocellulose membrane at the speed of 2 muL/cm and 3 muL/cm by using a colloidal gold spraying apparatus, respectively serving as a high-concentration detection line and a low-concentration detection line, wherein the distances between the detection lines and a gold label pad are respectively 0.8mm and 5.2mm, further taking an anti-BSA antibody solution to dilute to the concentration of 1.6mg/mL, spraying the solution onto the nitrocellulose membrane at the speed of 3 muL/cm by using the colloidal gold spraying apparatus as a quality control line, wherein the distance between the detection lines and the gold label pad is 16.5mm, and then placing the nitrocellulose membrane into a 27-DEG C oven to bake for 2 hours, and then taking out to obtain a chromatography pad for later use.

(5) The sample pad, the gold label pad, the chromatography pad and the water absorption pad are sequentially adhered to a Plastic (PVC) bottom plate, the length of the overlapped part of each component and the adjacent component is 2mm, the components are cut into test strips with the width of 3mm by a slitter and the test strips are stored at normal temperature for standby.

Embodiment 2 the structure of a lamotrigine lateral flow assay test strip with multiple concentration detection lines provided in this embodiment is substantially the same as that in embodiment 1, except that the preparation method of the test strip includes the following steps:

(1) preparation of gold nanoparticles for labeling: 50mL of double distilled water is poured into a 250mL conical flask, 850 mu L of chloroauric acid with the concentration of 5mg/mL is dripped into the double distilled water, and the double distilled water is placed on a magnetic heating stirrer to be heated to slight boiling. When the liquid in the conical flask is slightly boiled, keeping the stirring speed of 1500r/min unchanged, and then rapidly adding 750 mu L of trisodium citrate solution with the mass concentration of 10 g/L. The color of the solution is changed obviously within 2min from transparent-black-purple-wine red to unchanged color, the heat source is closed, the solution is stirred for 5min, and the solution is cooled to obtain the colloidal gold solution, wherein the particle size distribution of the contained nano gold particles is 18-40nm, and the colloidal gold solution is stored at 4 ℃ for standby.

(2) Preparation of colloidal gold marker: putting 500 mu L of the colloidal gold solution prepared in the step (1) into a clean and dry 1.5mL centrifuge tube, adding 1.5 mu L of potassium carbonate solution with the concentration of 0.3M, uniformly mixing by oscillation, adding 1.5-5 mu L of lamotrigine monoclonal antibody solution with the concentration of about 1mg/mL, carrying out oscillation reaction for 1h, then adding 50 mu L of BSA solution with the concentration of 10 wt%, continuing oscillation reaction for 0.5h, centrifuging at 10100r/min for 10min, separating out red precipitate, and re-dissolving by 50 mu L of BSA solution with the concentration of 20 wt%, thus obtaining colloidal gold marker dispersion;

(3) preparing a gold label pad: and dropwise adding the colloidal gold marker dispersion liquid to a nitrocellulose membrane for preparing the gold-labeled pad according to the dosage of 4 mu L/pad, and drying in an oven at 27 ℃ to obtain the gold-labeled pad for later use.

(4) Preparation of the chromatographic pad: and (2) taking the lamotrigine-bovine serum albumin conjugate solution to respectively dilute to 0.8mg/mL and 0.1mg/mL, respectively spraying the solution onto a nitrocellulose membrane at the speed of 1 muL/cm and 1 muL/cm by using a colloidal gold spraying instrument, respectively serving as a high-concentration detection line and a low-concentration detection line, wherein the distances between the detection lines and a gold label pad are respectively 1mm and 5.4mm, further taking the anti-BSA antibody solution to dilute to the concentration of 0.8mg/mL, spraying the solution onto the nitrocellulose membrane at the speed of 2 muL/cm by using the colloidal gold spraying instrument as a quality control line, wherein the distance between the detection lines and the gold label pad is 16.7mm, then placing the nitrocellulose membrane into a 27 ℃ oven to bake for 2 hours, and taking out to obtain the chromatography pad for later use.

(5) The sample pad, the gold label pad, the chromatography pad and the water absorption pad are sequentially adhered to a Plastic (PVC) bottom plate, the length of the overlapping part of each component and the adjacent component is 4mm, the components are cut into test strips with the width of 5mm by a slitter and the test strips are stored at normal temperature for standby.

Embodiment 3 the structure of a lamotrigine lateral flow assay test strip with multiple concentration detection lines provided in this embodiment is substantially the same as that in embodiment 1, except that the preparation method of the test strip includes the following steps:

(1) preparation of gold nanoparticles for labeling: 60mL of double distilled water is poured into a 250mL conical flask, 1000 μ L of chloroauric acid with the concentration of 8mg/mL is dripped into the double distilled water, and the double distilled water is placed on a magnetic heating stirrer to be heated to slight boiling. After the liquid in the conical flask is slightly boiled, keeping the stirring speed of 1500r/min unchanged, and then quickly adding 900 mu L of trisodium citrate solution with the mass concentration of 15 g/L. The color of the solution is changed obviously within 2min from transparent-black-purple-wine red to unchanged color, the heat source is closed, the solution is stirred for 10min, and the colloidal gold solution is obtained after cooling, wherein the particle size distribution of the contained nano gold particles is 18-40nm, and the colloidal gold solution is stored at 4 ℃ for standby.

(2) Preparation of colloidal gold marker: putting 800 mu L of the colloidal gold solution prepared in the step (1) into a clean and dry 1.5mL centrifuge tube, adding 2 mu L of potassium carbonate solution with the concentration of 0.5M, uniformly mixing by oscillation, adding 3 mu L of lamotrigine monoclonal antibody solution with the concentration of about 1mg/mL, carrying out oscillation reaction for 2 hours, adding 80 mu L of BSA solution with the concentration of 10 wt%, continuing oscillation reaction for 1 hour, centrifuging for 20 minutes at 10100r/min, separating out red precipitate, and redissolving by 50 mu L of BSA solution with the concentration of 10 wt%, thus obtaining colloidal gold marker dispersion;

(3) preparing a gold label pad: and dropwise adding the colloidal gold marker dispersion liquid to a nitrocellulose membrane for preparing the gold-labeled pad according to the dosage of 6 mu L/pad, and drying in an oven at 27 ℃ to obtain the gold-labeled pad for later use.

(4) Preparation of the chromatographic pad: and (2) taking the lamotrigine-bovine serum albumin conjugate solution to respectively dilute to 1.0mg/mL and 0.2mg/mL, respectively spraying the solution onto a nitrocellulose membrane at the speeds of 4 muL/cm and 4 muL/cm by using a colloidal gold spraying instrument, respectively serving as a high-concentration detection line and a low-concentration detection line, wherein the distances between the detection lines and a gold label pad are respectively 1.3mm and 5.7mm, further taking the anti-BSA antibody solution to dilute to the concentration of 1.0mg/mL, spraying the solution onto the nitrocellulose membrane at the speed of 5 muL/cm by using the colloidal gold spraying instrument as a quality control line, wherein the distance between the detection lines and the gold label pad is 17mm, then placing the nitrocellulose membrane into a 27 ℃ oven to bake for 2 hours, and taking out to obtain the chromatography pad for later use.

(5) Same as in example 1.

Embodiment 4 the structure of a lamotrigine lateral flow assay test strip with multiple concentration detection lines provided in this embodiment is substantially the same as that in embodiment 1, except that the preparation method of the test strip includes the following steps:

(1) preparation of gold nanoparticles for labeling: according to the method reported by literatures (such as "synthesis, properties and new application of gold nanoparticles", zhanju and the like, "university of Jilin university book (Nature science edition)", 2017), a first colloidal gold solution and a second colloidal gold solution are prepared, wherein the particle size distribution of gold nanoparticles in the first colloidal gold solution is 1-5nm, the particle size distribution of gold nanoparticles in the second colloidal gold solution is 20-30nm, and then the first colloidal gold solution and the second colloidal gold solution are diluted to the same concentration and are diluted according to the ratio of 3: 2 volume ratio and mixing for standby.

(2) To (5): same as in example 1.

Embodiment 5 the structure of a lamotrigine lateral flow assay test strip with multiple concentration detection lines provided in this embodiment is substantially the same as that in embodiment 1, except that the preparation method of the test strip includes the following steps:

(1) preparation of gold nanoparticles for labeling: according to the method reported by literatures (such as "synthesis, properties and new application of gold nanoparticles", zhanju and the like, "university of Jilin university book (Nature science edition)", 2017), a first colloidal gold solution and a second colloidal gold solution are prepared, wherein the particle size distribution of gold nanoparticles in the first colloidal gold solution is 5-10nm, the particle size distribution of gold nanoparticles in the second colloidal gold solution is 30-50nm, and then the first colloidal gold solution and the second colloidal gold solution are diluted to the same concentration and are diluted to 7: 3, and mixing for later use.

(2) To (5): same as in example 1.

Embodiment 6 the structure of a lamotrigine lateral flow assay test strip with multiple concentration detection lines provided in this embodiment is substantially the same as that in embodiment 4, except that the preparation method of the test strip includes the following steps:

(1) preparation of gold nanoparticles for labeling: according to the method reported by literatures (such as synthesis, properties and new application of gold nanoparticles, Dianthus hai, and the like, university of Jilin, Nature's institute of technology, Nature's edition, 2017), a colloidal gold solution is prepared, and the particle size distribution of the gold nanoparticles in the colloidal gold solution is 5-10 nm.

(2) To (5): same as in example 1.

Embodiment 7 the structure of a lamotrigine lateral flow assay test strip with multiple concentration detection lines provided in this embodiment is substantially the same as that in embodiment 4, except that the test strip preparation method comprises the following steps:

(1) preparation of gold nanoparticles for labeling: according to the method reported by literatures (such as synthesis, properties and new application of gold nanoparticles, Dianthus hai, and the like, university of Jilin, Nature's institute of technology, Nature's edition, 2017), a colloidal gold solution is prepared, and the particle size distribution of the gold nanoparticles in the colloidal gold solution is 30-50 nm.

(2) To (5): same as in example 1.

Taking fingertip blood samples of a plurality of patients taking lamotrigine with different dosages, respectively and directly dripping each blood sample on the sample pad of the test strip prepared in the embodiment 1-embodiment 7, wherein the dripping amount of the blood sample on each test strip is 60-100 mu L, then waiting for 10-15min, observing the color development conditions of a high-concentration detection line, a low-concentration detection line and a quality control line on each test strip, and directly judging the concentration range of lamotrigine in each blood sample according to the color development result, referring to fig. 2, the relevant judgment basis is as follows:

when the concentration of lamotrigine in the blood sample is higher than or equal to 15 mug/mL, the lamotrigine with higher concentration effectively inhibits both the high-concentration detection line and the low-concentration detection line, and only a quality control line is displayed on each paper strip, so that the lamotrigine concentration in the blood sample can be quickly judged to be higher than 15 mug/mL.

When the concentration of lamotrigine in a blood sample is higher than or equal to 2.5 mug/mL but less than 15 mug/mL, the concentration of lamotrigine in the sample can completely inhibit the low-concentration detection line on each test strip, the high-concentration detection line is partially inhibited but still can be shown, the quality control line is completely shown, namely only the quality control line and the high-concentration detection line are shown, and the concentration of lamotrigine in the blood sample can be rapidly judged to be between 2.5 and 15 mug/mL.

When the concentration of lamotrigine in the blood sample is less than 2.5 mug/mL, the concentration of lamotrigine in the sample cannot cause the inhibition phenomenon of a low-concentration detection line and a high-concentration detection line, the low-concentration detection line and the high-concentration detection line can be displayed, a quality control line is completely displayed, and the concentration of lamotrigine in the blood sample can be rapidly judged to be less than 2.5 mug/mL.

Fig. 3 shows the color development of each detection line and quality control line after the test strip of example 1 tests blood samples containing lamotrigine with different concentrations. The test strips of examples 2-7 also performed similarly.

In addition, the concentration of lamotrigine in each blood sample is tested by an HPLC method so as to verify the accuracy of the detection result of each test strip.

While the invention has been described with reference to illustrative embodiments, it will be understood by those skilled in the art that various other changes, omissions and/or additions may be made and substantial equivalents may be substituted for elements thereof without departing from the spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from its scope. For example, those skilled in the art can also construct a colloidal gold lateral chromatography test strip and a corresponding detection method for detecting other drugs with reference to the technical idea of the present invention. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed for carrying out this invention, but that the invention will include all embodiments falling within the scope of the appended claims.